



## **Novacea Selects Nextrials' Prism for Pivotal Phase III Prostate Cancer Trial**

*Biopharmaceutical firm initiates rollout of Prism<sup>®</sup> to facilitate the collection and management of clinical data in new study*

**San Ramon, CA – January 9, 2006** – Nextrials, Inc., a leader in clinical research software and services, today announced that Novacea, Inc., a privately held biopharmaceutical company, has selected its flagship Prism<sup>®</sup> Electronic Data Capture (EDC) software for use in a long-term Phase III study of a novel therapeutic for the treatment of prostate cancer.

“Novacea is one of the few pharmaceutical companies in the industry to employ 100 percent electronic data capture for all clinical trials,” said Nicholas Gould, associate director, clinical systems for Novacea. “In order to achieve this, we need the support of networking products that are especially robust and stable. Our previous experience with Nextrials' Prism has shown that it has achieved the Holy Grail of 100 percent uptime. This fact, coupled with its other capabilities such as patient randomization and drug inventory management, has earned our loyalty as a customer.”

Prism is the first product designed specifically for the biotechnology, pharmaceutical and medical device markets that pulls together all of the components of managing clinical trials research into a comprehensive, web-enabled system. By combining data management, advanced safety requirements, inventory control and other related services into a unified application, data can be easily and quickly collected, collapsed and centralized, delivering an accurate and timely picture of an ongoing study. This is especially important for large, multi-site clinical trials, as Prism increases the industry's ability to conduct significant, complex clinical research in a safe and cost-effective environment.

“Novacea has been one of the industry’s leaders in adopting new technologies that improve the process of conducting clinical trials,” said James Rogers, co-founder and CEO of Nextrials. “After conducting a competitive product analysis, Novacea selected Prism because it helps provide its researchers with key monitoring and safety features that help ensure the success of long- and short-term studies, especially those involving multiple test sites. Going forward, our goal will be to work closely with Novacea to ensure that Prism continues to deliver the capabilities the company requires to obtain and analyze clinical data in the most efficient manner possible.”

**About Nextrials, Inc.**

Founded by pharmaceutical researchers in 1999, Nextrials *Innovates for Life™* by offering today’s most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism®, its award-winning Electronic Data Capture (EDC) solution, has been used at over 200 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit [www.nextrials.com](http://www.nextrials.com) or call 925-355-3000.

##

Contacts:

James Rogers  
Nextrials, Inc.  
925-355-3000  
[jrogers@nextrials.com](mailto:jrogers@nextrials.com)

Nina Ferrari  
Novacea, Inc.  
650-228-1804  
[Ferrari@novacea.com](mailto:Ferrari@novacea.com)

Rachel V. Berry  
Sterling Communications  
253-853-5030  
[rberry@sterlingpr.com](mailto:rberry@sterlingpr.com)